Renal Cell Carcinoma Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape

Renal Cell Carcinoma Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Renal Cell Carcinomar therapeutics.

Synopsis

In 2022, there will be more than 1,490,000 diagnosed prevalent cases of renal cell carcinoma across 16 pharmaceutical markets.
There are 10 leading marketed drugs for the treatment of renal cell carcinoma, Merck is a key player in the disease space.
The renal cell carcinoma pipeline consists of 338 pharmaceuticals spanning all stages of development, with approximately 40% of drugs in mid to late-stage development.
Non-commercial sponsors dominate clinical trial development in renal cell carcinoma, with the US emerging as the key countries for conducting trials in renal cell carcinoma.
Deals involving partnerships are the most common type of deals globally.
Therapeutic options for renal cell carcinoma patients continue to be limited, with only one new therapy expected to reach the US market in the next 18 months.

Scope

GlobalData’s Renal Cell Carcinoma Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

Disease Landscape
Disease Overview
Epidemiology Overview
Treatment Overview
Marketed Products Assessment
Breakdown by Mechanism of Action, Molecule Type and Route of Administration
Product Profiles with Sales Forecast
Pipeline Assessment
Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
Late-to-mid-stage Pipeline Drugs
Phase Transition Success Rate and Likelihood of Approval
Clinical Trials Assessment
Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
Enrolment Analytics, Site Analytics, Feasibility Analysis
Deals Landscape
Mergers, Acquisitions, and Strategic Alliances by Region
Overview of Recent Deals
Commercial Assessment
Key Market Players
Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Renal Cell Carcinomar market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Renal Cell Carcinomar market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.